Literature DB >> 28304097

Improved Screening Test for Idiopathic Infantile Hypercalcemia Confirms Residual Levels of Serum 24,25-(OH)2 D3 in Affected Patients.

Martin Kaufmann1, Nicole Morse1, Billy Joe Molloy2, Donald P Cooper2, Karl Peter Schlingmann3, Arnaud Molin4,5, Marie Laure Kottler4,5, J Christopher Gallagher6, Laura Armas7, Glenville Jones1.   

Abstract

CYP24A1 mutations are now accepted as a cause of idiopathic infantile hypercalcemia (IIH). A rapid liquid-chromatography tandem mass spectrometry (LC-MS/MS)-based blood test enabling measurement of the 25-OH-D3 :24,25-(OH)2 D3 ratio (R) can identify IIH patients on the basis of reduced C24-hydroxylation of 25-OH-D3 by CYP24A1 in vivo. Although values of this ratio are significantly elevated in IIH, somewhat surprisingly, serum 24,25-(OH)2 D3 remains detectable. The current study explores possible explanations for this including: residual CYP24A1 enzyme activity in individuals with certain CYP24A1 genotypes, expression of alternative C24-hydroxylases, and the possibility of isobaric contamination of the 24,25-(OH)2 D3 peak on LC-MS/MS. We employed an extended 20-min run time on LC-MS/MS to study serum vitamin D metabolites in patients with IIH due to mutations of CYP24A1 or SLC34A1; in unaffected heterozygotes and dialysis patients; in patients with vitamin D deficiency; as well as in normal subjects exhibiting a broad range of 25-OH-D levels. We identified 25,26-(OH)2 D3 as a contaminant of the 24,25-(OH)2 D3 peak. In normals, the concentration of 24,25-(OH)2 D3 greatly exceeds 25,26-(OH)2 D3 ; however, 25,26-(OH)2 D3 becomes more significant in IIH with CYP24A1 mutations and in dialysis patients, where 24,25-(OH)2 D3 levels are low when CYP24A1 function is compromised. Mean R in 30 IIH-CYP24A1 patients was 700 (range, 166 to 2168; cutoff = 140) as compared with 31 in 163 controls. Furthermore, patients possessing CYP24A1 L409S alleles exhibited higher 24,25-(OH)2 D3 levels and lower R (mean R = 268; n = 8) than patients with other mutations. We conclude that a chromatographic approach which resolves 24,25-(OH)2 D3 from 25,26-(OH)2 D3 produces a more accurate R that can be used to differentiate pathological states where CYP24A1 activity is altered. The origin of the residual serum 24,25-(OH)2 D3 in IIH patients appears to be multifactorial.
© 2017 American Society for Bone and Mineral Research. © 2017 American Society for Bone and Mineral Research.

Entities:  

Keywords:  24,25-(OH)2D3; 25,26-(OH)2D3; CYP24A1; HYPERCALCEMIA; LC-MS/MS

Mesh:

Substances:

Year:  2017        PMID: 28304097     DOI: 10.1002/jbmr.3135

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  16 in total

Review 1.  Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D.

Authors:  Christopher T Sempos; Annemieke C Heijboer; Daniel D Bikle; Jens Bollerslev; Roger Bouillon; Patsy M Brannon; Hector F DeLuca; Glenville Jones; Craig F Munns; John P Bilezikian; Andrea Giustina; Neil Binkley
Journal:  Br J Clin Pharmacol       Date:  2018-07-17       Impact factor: 4.335

2.  A kidney-specific genetic control module in mice governs endocrine regulation of the cytochrome P450 gene Cyp27b1 essential for vitamin D3 activation.

Authors:  Mark B Meyer; Nancy A Benkusky; Martin Kaufmann; Seong Min Lee; Melda Onal; Glenville Jones; J Wesley Pike
Journal:  J Biol Chem       Date:  2017-08-14       Impact factor: 5.157

3.  A chromatin-based mechanism controls differential regulation of the cytochrome P450 gene Cyp24a1 in renal and non-renal tissues.

Authors:  Mark B Meyer; Seong Min Lee; Alex H Carlson; Nancy A Benkusky; Martin Kaufmann; Glenville Jones; J Wesley Pike
Journal:  J Biol Chem       Date:  2019-08-22       Impact factor: 5.157

4.  The metabolism of 1,25(OH)2D3 in clinical and experimental kidney disease.

Authors:  Mandy E Turner; Tyler S Rowsell; Christine A White; Martin Kaufmann; Patrick A Norman; Kathryn Neville; Martin Petkovich; Glenville Jones; Michael A Adams; Rachel M Holden
Journal:  Sci Rep       Date:  2022-06-28       Impact factor: 4.996

5.  Targeted genomic deletions identify diverse enhancer functions and generate a kidney-specific, endocrine-deficient Cyp27b1 pseudo-null mouse.

Authors:  Mark B Meyer; Nancy A Benkusky; Martin Kaufmann; Seong Min Lee; Robert R Redfield; Glenville Jones; J Wesley Pike
Journal:  J Biol Chem       Date:  2019-05-03       Impact factor: 5.157

6.  Elucidation of metabolic pathways of 25-hydroxyvitamin D3 mediated by Cyp24a1 and Cyp3a using Cyp24a1 knockout rats generated by CRISPR/Cas9 system.

Authors:  Kaori Yasuda; Miyu Nishikawa; Kairi Okamoto; Kyohei Horibe; Hiroki Mano; Mana Yamaguchi; Risa Okon; Kimie Nakagawa; Naoko Tsugawa; Toshio Okano; Fumihiro Kawagoe; Atsushi Kittaka; Shinichi Ikushiro; Toshiyuki Sakaki
Journal:  J Biol Chem       Date:  2021-04-15       Impact factor: 5.157

7.  Validation of the 24,25-dihydroxyvitamin D3 to 25-hydroxyvitamin D3 ratio as a biomarker of 25-hydroxyvitamin D3 clearance.

Authors:  Simon Hsu; Leila R Zelnick; Yvonne S Lin; Cora M Best; Bryan R Kestenbaum; Kenneth E Thummel; Andrew N Hoofnagle; Ian H de Boer
Journal:  J Steroid Biochem Mol Biol       Date:  2021-12-22       Impact factor: 4.292

Review 8.  The Role of Vitamin D in CKD Stages 3 to 4: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Authors:  Michal L Melamed; Michel Chonchol; Orlando M Gutiérrez; Kamyar Kalantar-Zadeh; Jessica Kendrick; Keith Norris; Julia J Scialla; Ravi Thadhani
Journal:  Am J Kidney Dis       Date:  2018-10-05       Impact factor: 11.072

9.  Hereditary Hypercalcemia Caused by a Homozygous Pathogenic Variant in the CYP24A1 Gene: A Case Report and Review of the Literature.

Authors:  Daniele Cappellani; Alessandro Brancatella; Martin Kaufmann; Angelo Minucci; Edda Vignali; Domenico Canale; Elisa De Paolis; Ettore Capoluongo; Filomena Cetani; Glenville Jones; Claudio Marcocci
Journal:  Case Rep Endocrinol       Date:  2019-04-08

10.  Mild Idiopathic Infantile Hypercalcemia-Part 1: Biochemical and Genetic Findings.

Authors:  Nina Lenherr-Taube; Edwin J Young; Michelle Furman; Yesmino Elia; Esther Assor; David Chitayat; Tami Uster; Susan Kirwin; Katherine Robbins; Kathleen M B Vinette; Alan Daneman; Christian R Marshall; Carol Collins; Kenneth Thummel; Etienne Sochett; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.